{ "ok": true, "cik": "1907108", "ticker": "LXEO", "name": "Lexeo Therapeutics, Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-22", "items": [ "1.01 Entry into a Material Definitive Agreement", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/0001193125-26-397221-index.htm" }, { "form": "10-Q", "filed": "2026-08-12", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526345724/0001193125-26-345724-index.htm" }, { "form": "8-K", "filed": "2026-08-12", "items": [ "2.02 Results of Operations and Financial Condition", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/0001193125-26-345722-index.htm" }, { "form": "8-K", "filed": "2026-06-29", "items": [ "5.07 Submission of Matters to a Vote of Security Holders" ], "url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526288703/0001193125-26-288703-index.htm" }, { "form": "8-K", "filed": "2026-06-15", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/0001193125-26-270275-index.htm" }, { "form": "10-Q", "filed": "2026-05-11", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526215678/0001193125-26-215678-index.htm" } ], "events12m": 13, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001907108.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1907108" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up Lexeo Therapeutics, Inc. ($LXEO). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-22. 13 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2022-12-31", "revenue": 654000, "revenueGrowth1y": null, "revenueGrowthPerYear": null, "yearsOfData": 1, "operatingMargin": -92.52140672782875, "operatingMarginPrior": null, "netMargin": -90.63761467889908, "operatingCashFlow": -54560000, "capitalSpending": 672000, "freeCashFlow": -55232000, "researchAndDevelopment": 49162000, "researchShareOfRevenue": 75.17125382262996, "cash": 77335000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2022-12-31", "revenue": 654000 } ], "totalEquity": -112954000, "totalAssets": 97076000, "equityRatio": -1.1635625695331493, "returnOnEquity": null, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": -36.36, "sharesOutstanding": 1630348, "bookValuePerShare": -69.2821409907578, "revenuePerShare": 0.4011413514169981, "range80": null, "ifPaceHeld": null }, "edgarette": "🔖 Exposure: revenue $654K (FY2022). Experience: one year on record; operating margin -9252.1%. Soundness: equity -116.4% of assets (liabilities exceed assets). Credibility: one audited year, little weight. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -9252.1% against a -15.8% median.", "peers": { "sic": 2836, "sicDescription": "Biological Products, (No Diagnostic Substances)", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2836", "growth": [ 0.2145, 27 ], "opMargin": [ -0.1582, 31 ], "equityRatio": [ 0.5857, 31 ], "returnOnEquity": [ -0.0646, 25 ] }, "summary": "Lexeo Therapeutics (LXEO) reported revenue of $1 million in FY2022, operating margin -9252% against a -15.8% median for biological products, (no diagnostic substances), equity -116% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Lexeo Therapeutics, Inc. against its own record and its peers
Operating marginPeer median -15.8%-9252.1%Equity of assetsPeer median 58.6%-116.4%Gold tick: the median of 31–31 peers with $50M+ revenue in biological products, (no diagnostic substances)
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Lexeo Therapeutics (LXEO) reported revenue of $1 million in FY2022, operating margin -9252% against a -15.8% median for biological products, (no diagnostic substances), equity -116% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2022-12-31", "revenue": 654000, "totalDebt": null, "cash": 77335000 }, "experience": { "revenueGrowth1y": null, "revenueGrowthPerYear": null, "operatingMargin": -92.52140672782875, "operatingMarginPrior": null, "netMargin": -90.63761467889908, "freeCashFlow": -55232000 }, "soundness": { "equityRatio": -1.1635625695331493, "returnOnEquity": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2836, "sicDescription": "Biological Products, (No Diagnostic Substances)", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2836", "growth": [ 0.2145, 27 ], "opMargin": [ -0.1582, 31 ], "equityRatio": [ 0.5857, 31 ], "returnOnEquity": [ -0.0646, 25 ] }, "credibility": { "auditedYears": 1, "weight": "little", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": null, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001907108.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1907108" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }